Other STEAP metalloreductases such as STEAP4 and STEAP1 linked with prostate cancer progression as shown in studies by Gomes et al. (2014) and Jin et al. (2015) can be targets for suppression and or inhibition for their role in prostate cancer progression using inhibitory ligands. This evidence concerns the gene STEAP1 and prostate carcinoma.